Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Elana Judith Fertig

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3204-342X; OpenAlex author ID A5027701541; NIH RePORTER profile ID 9551759. Sources: OpenAlex.

Their work

Papers
28 (first author 0, last author 3)
Trials
0
Grants
3
Labs led
3
Collaborators
118
Papers, trials and grants by year

2020: 3 papers · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers · 2024: 4 papers · 2025: 4 papers, 1 grant · 2026: 10 papers, 2 grants

Papers 28

  1. GSTT1 promotes stemness and FGFR inhibitor sensitivity in pancreatic cancer through regulation of CD133 (PROM1). Co-author DOI 10.1016/j.canlet.2026.218733↗
  2. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Co-author DOI 10.1038/s41467-026-68324-4↗
  3. Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial Co-author DOI 10.1038/s41467-026-71968-x↗
  4. Patient-derived Organoid Pharmacotyping as a Predictive Tool for Therapeutic Selection in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006517↗
  5. Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-0331↗
  6. Asynchronous Evolution of Epithelium and Stroma Differentiates Precursor Lesions from Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-25-2001↗
  7. A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC. Co-author DOI 10.1158/2326-6066.cir-25-0545↗
  8. Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses. Co-author DOI 10.1158/2326-6066.cir-25-1126↗
  9. Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-25-1481↗
  10. Deep Learning Enabled 3D Multi-Omic Analysis Reveals Molecular Signatures of Heterogeneous Response to Chemotherapy in Pancreatic Cancer Co-author DOI 10.64898/2026.03.03.709150↗
  11. CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer clinical trial. Last author DOI 10.1016/j.isci.2024.111569↗
  12. Spatial profiling of human pancreatic ductal adenocarcinoma reveals molecular alterations associated with venous invasion. Co-author DOI 10.1126/scitranslmed.ady7524↗
  13. Human Pancreatic Cancer Single-Cell Atlas Reveals Association of CXCL10+ Fibroblasts and Basal Subtype Tumor Cells. Co-author DOI 10.1158/1078-0432.ccr-24-2183↗
  14. P4HA1 Mediates Hypoxia-Induced Invasion in Human Pancreatic Cancer Organoids. Co-author DOI 10.1158/2767-9764.crc-24-0025↗
  15. Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial. Co-author DOI 10.1038/s41467-024-52528-7↗
  16. Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer immunotherapy pathologic resp… Co-author DOI 10.1101/2024.09.22.613714↗
  17. Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Du… Co-author DOI 10.1158/0008-5472.can-23-1660↗
  18. Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.179292↗
  19. Morphology-guided transcriptomic analysis of human pancreatic cancer organoids reveals microenvironmental signals that enhance invasion. Co-author DOI 10.1172/jci162054↗
  20. Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy. Last author DOI 10.4049/jimmunol.2200660↗
  21. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Co-author DOI 10.1016/j.ccell.2022.10.001↗
  22. Inflammatory Signaling in Pancreatic Cancer Transfers Between a Single-cell RNA Sequencing Atlas and Co-Culture Co-author DOI 10.1101/2022.07.14.500096↗
  23. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarci… Co-author DOI 10.1136/jitc-2021-002837↗
  24. Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance. Co-author DOI 10.1158/2326-6066.cir-20-0272↗
  25. Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways. Last author DOI 10.1186/s13059-021-02363-6↗
  26. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-3978↗
  27. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1025↗
  28. Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma Development. Co-author DOI 10.1158/1940-6207.capr-20-0053↗

Grants 3

  1. Interrogation of the Impact of Selection on the Evolution of Human Pancreatic Cancer Precursor Lesions U01CA271273↗
  2. TBEL Project 3 U54CA274371↗
  3. An atlas of pancreatic tumorigenesis in the context of altered DNA repair occurring in high-risk individuals U01CA294548↗

Closest collaborators

The 25 strongest of 118 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Laura DeLong Wood · 6 shared papers, 3 shared grants, 2022–2026 · strength 3.61
  2. Elizabeth M. Jaffee · 18 shared papers, 2020–2026 · strength 2.92
  3. Won Jin Ho · 13 shared papers, 2020–2026 · strength 2.29
  4. Luciane Tsukamoto Kagohara · 11 shared papers, 2022–2026 · strength 1.88
  5. Robert A. Anders · 10 shared papers, 2020–2026 · strength 1.51
  6. Jacob T. Mitchell · 9 shared papers, 2022–2026 · strength 1.47
  7. Janelle Marie Montagne · 7 shared papers, 2022–2026 · strength 1.33
  8. Dimitrios N. Sidiropoulos · 8 shared papers, 2022–2026 · strength 1.32
  9. Jacquelyn W. Zimmerman · 8 shared papers, 2020–2026 · strength 1.19
  10. Jae Woo Lee · 6 shared papers, 2024–2026 · strength 1.15
  11. Katherine M. Bever · 6 shared papers, 2020–2026 · strength 1.07
  12. Marina Pasca di Magliano · 1 shared paper, 1 shared grant, 2026 · strength 1.07
  13. Anirban Maitra · 1 shared paper, 1 shared grant, 2026 · strength 1.07
  14. Rachel Karchin · 1 shared grant, 2026 · strength 1.00
  15. Lei Zheng · 7 shared papers, 2020–2026 · strength 0.94
  16. Hao Wang · 5 shared papers, 2022–2026 · strength 0.93
  17. Nicole Groß · 5 shared papers, 2021–2026 · strength 0.82
  18. Mark M. Yarchoan · 5 shared papers, 2021–2026 · strength 0.78
  19. Dung Thi Le · 5 shared papers, 2020–2026 · strength 0.78
  20. Jin Peng He · 5 shared papers, 2022–2026 · strength 0.78
  21. Rosalie C. Sears · 1 shared grant, 2025 · strength 0.73
  22. Jonathan Robert Brody · 1 shared grant, 2025 · strength 0.73
  23. Samantha R. Guinn · 4 shared papers, 2022–2026 · strength 0.68
  24. Daniel A. Laheru · 5 shared papers, 2020–2026 · strength 0.65
  25. Amanda L. Huff · 3 shared papers, 2026 · strength 0.61

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.